NCT04554940View on ClinicalTrials.gov

A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 10, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Achondroplasia
Interventions
BIOLOGICAL

vosoritide

Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

Trial Locations (3)

3052

Murdoch Children's Research Institute, Parkville

SE1 7EH

Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital, London

S10 2TH

Sheffield Children's NHS Foundation Trust, Sheffield

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY